CELL INTELLIGENCE · 肿瘤细胞治疗研究

序贯 CD2/CD3/CD28 激活改善 T 细胞受体 α 恒定区的非病毒大载荷嵌合抗原受体敲入

Sequential CD2/CD3/CD28 activation improves nonviral large-payload chimeric antigen receptor knock-in at the T cell receptor α constant locus.

非基因编辑、靶向 CD19 的同种异体 CAR-T 细胞疗法治疗复发/难治性 B 细胞急性淋巴细胞白血病：一项开放标签、单臂 1 期研究

Non-gene-edited, CD19-targeted, allogeneic CAR-T cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia: an open-label, single-ar

TP53 缺失诱导与 B-ALL 中 CAR-T 细胞耗竭加速相关的低黏附转录组特征

TP53 deficiency induces a low-adhesion transcriptomic signature correlating with accelerated CAR-T cell exhaustion in B-ALL.

我们的体外研究结果表明，B-ALL 细胞中 TP53 缺失会下调黏附网络并损害免疫原性信号，这与 CAR-T 细胞耗竭加速相关。

内在性 NPRL2 与 NPRL3 调控 B 细胞恶性肿瘤对 CAR-T 细胞治疗的敏感性

Intrinsic NPRL2 and NPRL3 regulate the sensitivity of B-cell malignancies to CAR-T cell therapy.

PSMB9 调控肿瘤免疫格局并作为预后与 T 细胞免疫治疗应答的强效生物标志物

PSMB9 Orchestrates Tumor Immune Landscape and Serves as a Potent Biomarker for Prognosis and T Cell-Based Immunotherapy Response.

通过脂质纳米颗粒共递送多种 RNA 实现 CAR-T 细胞的精准基因编辑

Co-Delivery of Multiple RNAs via Lipid Nanoparticles Enables Precise Gene Editing of CAR-T Cells.

利用 CRISPR/Cas9 技术构建抗 CD19 CAR 敲入人诱导多能干细胞系

Generation of an anti-CD19 CAR knock-in human induced pluripotent stem cell line using CRISPR/Cas9 technology.

CAR-T 细胞治疗在急性髓系白血病中的突破：ASH 2024 更新

Breakthroughs of CAR T-cell therapy in acute myeloid leukemia: updates from ASH 2024.

IL-2 诱导型 T 细胞激酶缺陷维持 CAR-T 细胞抗肿瘤细胞的治疗作用

IL-2-inducible T cell kinase deficiency sustains chimeric antigen receptor T cell therapy against tumor cells.

靶向自噬克服 B 细胞恶性肿瘤中肿瘤内在的 CAR-T 免疫治疗耐药

Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies.

这些发现证实，B 细胞恶性肿瘤中的自噬信号对于 CAR-T 细胞的有效细胞毒性功能至关重要，从而为开发靶向自噬的策略以提高 CAR-T 细胞免疫疗法的临床疗效铺平了道路。